RxDoctor Payments Data

Elizabeth Cooley, MD

Family Medicine · Utica, NYNPI 1871748020

Payments from drug & device makers

$938in general payments, 2019–2025

Across 14 payments — averaging $67.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$411
  • Neurocrine Biosciences, Inc.$234
  • SK Life Science, Inc.$125
  • AstraZeneca$105
  • Johnson & Johnson$17
  • Novo Nordisk$17
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$938 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$74,415
Medicare patients
472
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$64,090
OzempicSemaglutide25$44,773
JardianceEmpagliflozin38$39,708
JanuviaSitagliptin Phosphate48$34,391
XifaxanRifaximin14$29,167
FarxigaDapagliflozin Propanediol20$26,130
TrulicityDulaglutide24$24,651
RybelsusSemaglutide12$22,988
XareltoRivaroxaban24$20,846
LinzessLinaclotide19$14,215
RexultiBrexpiprazole21$14,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,946
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$11,328
MyrbetriqMirabegron17$9,953
Incruse ElliptaUmeclidinium Bromide21$7,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$17$67,76137 claims
PfizerEliquis$15$64,090148 claims
AstraZenecaFarxiga, Symbicort$105$33,41934 claims
Johnson & JohnsonXarelto$17$20,84624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →